Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy

被引：0

作者：

Yoshiaki Nakamura

Takeharu Yamanaka

Keisho Chin

Haruhiko Cho

Hitoshi Katai

Masanori Terashima

Kazunari Misawa

Motohiro Hirao

Kazuhiro Yoshida

Eiji Oki

Mitsuru Sasako

Yasunori Emi

Hideaki Bando

Yoshiyuki Kawashima

Tetsu Fukunaga

Masahiro Gotoh

Takako Ishibashi

Kohei Shitara

机构：

[1] National Cancer Center Hospital East,Department of Gastroenterology and Gastrointestinal Oncology

[2] Yokohama City University,Department of Biostatistics

[3] Cancer Institute Hospital of Japanese Foundation for Cancer Research,Department of Gastroenterology

[4] Kanagawa Cancer Center,Department of Gastrointestinal Surgery

[5] Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,Department of Surgery

[6] National Cancer Center Hospital,Division of Gastric Surgery

[7] Shizuoka Cancer Center,Division of Gastric Surgery

[8] Aichi Cancer Center Hospital,Department of Gastroenterological Surgery

[9] National Hospital Organization Osaka National Hospital,Department of Surgery

[10] Gifu University,Department of Surgical Oncology, Graduate School of Medicine

[11] Kyushu University Hospital,Department of Surgery and Science, Graduate School of Medical Sciences

[12] Hyogo College of Medicine,Department of Surgery

[13] Saiseikai Fukuoka General Hospital,Department of Surgery

[14] Saitama Cancer Center,Department of Gastroenterological Surgery

[15] St. Marianna University School of Medicine,Department of Gastroenterological and General Surgery

[16] Osaka Medical College,Cancer Chemotherapy Center

[17] Yokohama City University Hospital,Center for Novel and Exploratory Clinical Trials

来源：

Annals of Surgical Oncology | 2019年 / 26卷

关键词：

Capecitabine Plus Oxaliplatin (CAPOX); Survival Outcomes; Gastric Cancer; pStage; Histological Type;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：465 / 472

页数：7

共 50 条

[1] Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy
Nakamura, Yoshiaki
Yamanaka, Takeharu
Chin, Keisho
Cho, Haruhiko
Katai, Hitoshi
Terashima, Masanori
Misawa, Kazunari
Hirao, Motohiro
Yoshida, Kazuhiro
Oki, Eiji
Sasako, Mitsuru
Emi, Yasunori
Bando, Hideaki
Kawashima, Yoshiyuki
Fukunaga, Tetsu
Gotoh, Masahiro
Ishibashi, Takako
Shitara, Kohei
ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (02) : 465 - 472
[2] Three-year outcomes of two phase II studies of adjuvant chemotherapy with S-1 plus oxaliplatin or capecitabine plus oxaliplatin in patients with stage III gastric cancer after D2 gastrectomy
Nakamura, Yoshiaki
Yamanaka, Takeharu
Chin, Keisho
Cho, Haruhiko
Katai, Hitoshi
Terashima, Masanori
Ito, Seiji
Hirao, Motohiro
Yoshida, Kazuhiro
Oki, Eiji
Sasako, Mitsuru
Emi, Yasunori
Bando, Hideaki
Kawashima, Yoshiyuki
Fukunaga, Tetsu
Gotoh, Masahiro
Ishibashi, Takako
Shitara, Kohei
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[3] Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy
Shitara, Kohei
Chin, Keisho
Yoshikawa, Takaki
Katai, Hitoshi
Terashima, Masanori
Ito, Seiji
Hirao, Motohiro
Yoshida, Kazuhiro
Oki, Eiji
Sasako, Mitsuru
Emi, Yasunori
Tsujinaka, Toshimasa
GASTRIC CANCER, 2017, 20 (01) : 175 - 181
[4] Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy
Kohei Shitara
Keisho Chin
Takaki Yoshikawa
Hitoshi Katai
Masanori Terashima
Seiji Ito
Motohiro Hirao
Kazuhiro Yoshida
Eiji Oki
Mitsuru Sasako
Yasunori Emi
Toshimasa Tsujinaka
Gastric Cancer, 2017, 20 : 175 - 181
[5] Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study
Nozomu Fuse
Hideaki Bando
Keisho Chin
Seiji Ito
Takaki Yoshikawa
Akira Tsuburaya
Masanori Terashima
Yoshiyuki Kawashima
Tetsu Fukunaga
Masahiro Gotoh
Yasunori Emi
Kazuhiro Yoshida
Eiji Oki
Seiji Takahashi
Hiroshi Kuriki
Kumi Sato
Mitsuru Sasako
Gastric Cancer, 2017, 20 : 332 - 340
[6] Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study
Fuse, Nozomu
Bando, Hideaki
Chin, Keisho
Ito, Seiji
Yoshikawa, Takaki
Tsuburaya, Akira
Terashima, Masanori
Kawashima, Yoshiyuki
Fukunaga, Tetsu
Gotoh, Masahiro
Emi, Yasunori
Yoshida, Kazuhiro
Oki, Eiji
Takahashi, Seiji
Kuriki, Hiroshi
Sato, Kumi
Sasako, Mitsuru
GASTRIC CANCER, 2017, 20 (02) : 332 - 340
[7] Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy
Cho, Jang Ho
Lim, Jae Yun
Cho, Jae Yong
PLOS ONE, 2017, 12 (10):
[8] Capecitabine Plus Oxaliplatin Versus Capecitabine Plus Oxaliplatin with Concurrent Radiation Therapy in the Treatment of Gastric Cancer after D2 Gastrectomy
Xie, C.
Chen, D.
Jin, X.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S28 - S29
[9] Capecitabine plus oxaliplatin versus capecitabine plus oxaliplatin with concurrent radiotherapy in the treatment of gastric cancer after D2 gastrectomy.
Xie, Congying
Jin, Xiance
Chen, Didi
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[10] Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
Yu, Yuanyuan
Zhang, Zicheng
Meng, Qianhao
Ma, Yue
Fan, Xiaona
Sun, Jie
Wang, Guangyu
FRONTIERS IN ONCOLOGY, 2021, 11

← 1 2 3 4 5 →